Update shared on06 Aug 2025
Fair value Increased 6.38%Lineage Cell Therapeutics' higher net profit margin and a slight increase in its discount rate have contributed to a raised consensus analyst price target, now at $4.17.
What's in the News
- First-ever chronic spinal cord injury patient treated in Lineage's DOSED clinical study, which evaluates a novel device for delivering OPC1 cells directly to injury sites; OPC1 has received RMAT and Orphan Drug designations from the FDA.
- 36-month Phase 1/2a data for OpRegen (RG6501) in geographic atrophy secondary to AMD showed sustained retinal structural improvement in treated eyes, suggesting durable therapeutic benefit; ongoing Phase 2a study (GAlette) is evaluating delivery methods and surgical parameters.
- Worldwide collaboration on OpRegen with Roche and Genentech continues, with clinical results presented at Clinical Trials at the Summit, a major industry event.
- Auditor Moss Adams merged with Baker Tilly, which has been approved as Lineage’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.
Valuation Changes
Summary of Valuation Changes for Lineage Cell Therapeutics
- The Consensus Analyst Price Target has risen from $3.92 to $4.17.
- The Net Profit Margin for Lineage Cell Therapeutics has significantly risen from 10.54% to 12.26%.
- The Discount Rate for Lineage Cell Therapeutics has risen from 6.40% to 6.78%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.